This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
by Zacks Equity Research
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
by Zacks Equity Research
Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
by Zacks Equity Research
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
by Zacks Equity Research
Philips (PHG) is launching cardiac solutions to further benefit from its tried-and-tested strategic operational decision to build new products to attract more customers.
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
by Zacks Equity Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
by Zacks Equity Research
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
Philips (PHG) Expands Partnership to Build Angio CT Solution
by Zacks Equity Research
Philips (PHG) is building the world's first spectral detector angio CT solution by forging an alliance with the Leiden University Medical Center.
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
by Zacks Equity Research
Philips (PHG) cautions customers against health hazards faced by the users of CPAP or Bi-Level PAP therapy masks with magnetic headgear.
New Strong Sell Stocks for July 28th
by Zacks Equity Research
ACER, BAK, and CJPRY have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2022.
New Strong Sell Stocks for July 15th
by Zacks Equity Research
ACER, HMN, and STT have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2022.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
ACER, CAH, and DRI have been added to the Zacks Rank #5 (Strong Sell) List on July 8, 2022.
New Strong Sell Stocks for June 28th
by Zacks Equity Research
ACER, BA, and LOB have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2022.
New Strong Sell Stocks for June 23rd
by Zacks Equity Research
ACER, PRG, and ALX have been added to the Zacks Rank #5 (Strong Sell) List on June 23, 2022.
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug
by Zacks Equity Research
Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.
New Strong Sell Stocks for June 21st
by Zacks Equity Research
ALYA, ALGN, and ACER have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2022.
New Strong Sell Stocks for June 15th
by Zacks Equity Research
ACER, AHCHY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2022.
New Strong Sell Stocks for June 9th
by Zacks Equity Research
ALX, ACER, and SBFG have been added to the Zacks Rank #5 (Strong Sell) List on June 9, 2022.
New Strong Sell Stocks for June 6th
by Zacks Equity Research
ACER, RACE, and PYPL have been added to the Zacks Rank #5 (Strong Sell) List on June 6, 2022.
New Strong Sell Stocks for May 27th
by Zacks Equity Research
ACER, BBWI, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2022.
Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Acer Therapeutics Inc. (ACER) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)
by Zacks Equity Research
Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year.